Some studies have targeted the detrimental effects of gut dysbiosis in NAFLD by using microbiota-regulating drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes (81). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.